Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from An engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Bladder cancer: a review
10.1001/jama.2020.17598 · 2020 · External reference
Bladder cancer: diagnosis and treatment
2017 · External reference
Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis
10.1634/theoncologist.2015-0440 · 2016 · External reference
Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis
10.4103/0973-1482.188434 · 2018 · External reference
A cycloruthenated complex, ruthenium (II) Z (RuZ) overcomes in vitro and in vivo multidrug resistance in cancer cells: a pivotal breakthrough
10.2478/jtim-2023-0081 · 2023 · External reference
Beyond tumour suppression: cgas-sting pathway in urologic malignancies: context-dependent duality and therapeutic implications
10.1002/ctm2.70531 · 2025 · External reference
Interference of ATP-adenosine axis by engineered biohybrid for amplifying immunogenic cell death-mediated antitumor immunotherapy
10.1002/adma.202405673 · 2024 · External reference
Improving Anti-PD-1/PD-L1 therapy for localized bladder cancer
10.3390/ijms22062800 · 2021 · External reference
Biomineralized engineered bacterial outer membrane vesicles as cGAS-STING nanoagonists synergize with lactate metabolism modulation to potentiate immunotherapy
10.1021/jacs.5c05148 · 2025 · External reference
Mucoadhesive vs. mucopenetrating particulate drug delivery
10.1016/j.ejpb.2015.11.003 · 2016 · External reference
Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy
10.1016/j.ijpharm.2014.05.014 · 2014 · External reference
Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets
2025 · External reference
Treatment strategies and metabolic pathway regulation in urothelial cell carcinoma: a comprehensive review
10.3390/ijms21238993 · 2020 · External reference
Recurrent bladder cancer in aging societies: importance of major histocompatibility complex class I antigen presentation
10.1002/ijc.33359 · 2021 · External reference
Precision phototherapy and imaging with aggregation-induced emission-based nanoparticles cloaked in macrophage membrane
10.1515/mr-2024-0041 · 2025 · External reference
Engineered radiation-sensitive probiotic for synergistic tumor cell cycle blockade and immunomodulation to potentiate radio-immunotherapy in pancreatic cancer
10.1016/j.mattod.2025.03.018 · 2025 · External reference
Bimetallic nanoreactor mediates cascade amplification of oxidative stress for complementary chemodynamic-immunotherapy of tumor
10.1016/j.biomaterials.2024.123075 · 2025 · External reference
NAT10 drives cisplatin chemoresistance by enhancing ac4C-Associated DNA repair in bladder cancer
10.1158/0008-5472.can-22-2233 · 2023 · External reference
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
10.1186/s12943-022-01517-9 · 2022 · External reference
Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by enhancing nucleotide excision repair in bladder cancer
10.1186/s13046-025-03487-4 · 2025 · External reference
Targeting the KAT8/YEATS4 axis represses tumor growth and increases cisplatin sensitivity in bladder cancer
2024 · External reference
Downregulated XPA promotes carcinogenesis of bladder cancer via impairment of DNA repair
10.1177/1010428317691679 · 2017 · External reference
Impact of DNA repair deficiency in the evolving treatment landscape of bladder cancer
10.1007/s11934-024-01242-4 · 2024 · External reference
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
10.1038/s41573-019-0016-5 · 2019 · External reference
AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer
10.1038/s41467-023-41218-5 · 2023 · External reference
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy
10.1136/jitc-2024-009368 · 2024 · External reference
STING-induced regulatory B cells compromise NK function in cancer immunity
10.1038/s41586-022-05254-3 · 2022 · External reference
SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression
10.1158/1078-0432.ccr-23-1439 · 2023 · External reference
Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming
10.1126/sciadv.aay9789 · 2020 · External reference
European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines
10.1016/j.eururo.2020.03.055 · 2021 · External reference
Metabolic alterations in bladder cancer: applications for cancer imaging
10.1016/j.yexcr.2016.01.005 · 2016 · External reference
Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer
10.1002/cam4.1109 · 2017 · External reference
The pentose phosphate pathway and cancer
10.1016/j.tibs.2014.06.005 · 2014 · External reference
PD-1/PD-L1 combinations in advanced urothelial cancer: Rationale and current clinical trials
10.1016/j.clgc.2019.03.009 · 2019 · External reference
On the origin of cancer cells
10.1126/science.123.3191.309 · 1956 · External reference
Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy
10.1016/j.celrep.2019.08.068 · 2019 · External reference
Inosine is an alternative carbon source for CD8(+)-T-cell function under glucose restriction
10.1038/s42255-020-0219-4 · 2020 · External reference
Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses
10.1016/j.cell.2015.08.012 · 2015 · External reference
LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells
10.1016/j.cmet.2016.08.011 · 2016 · External reference
Inhibitory effect of tumor cell-derived lactic acid on human T cells
10.1182/blood-2006-07-035972 · 2007 · External reference
Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions
10.1371/journal.pbio.1002202 · 2015 · External reference
Neutralization of tumor acidity improves antitumor responses to immunotherapy
10.1158/0008-5472.can-15-1743 · 2016 · External reference
Blockade of lactate Dehydrogenase-A (LDH-A) improves efficacy of anti-programmed cell Death-1 (PD-1) therapy in Melanoma
10.3390/cancers11040450 · 2019 · External reference
